Oligonucleotides News and Research

RSS

Oligonucleotides are short sequences of nucleotides (RNA or DNA), typically with twenty or fewer bases. Automated synthesizers allow the synthesis of oligonucleotides up to 160 to 200 bases.

Bristol-Myers Squibb collaborates with Isis Pharmaceuticals

Bristol-Myers Squibb Company and Isis Pharmaceuticals have announced a collaboration to discover, develop and commercialize novel antisense drugs targeting proprotein convertase subtilisin kexin 9 (PCSK9) for the prevention and treatment of cardiovascular disease.

10 May 2007

Scientists test technique for identifying newly recognized DNA variations that may influence disease risk

Rather than focus on errors and alterations in DNA sequence, the new technique highlights variations in the number of copies of a particular gene.

30 Jan 2007

Nanoparticles yield delivery tools for therapeutic nucleic acids

Cancer researchers hold great hope that nucleic acid-based therapeutics, such as anticancer genes, antisense oligonucleotides, and small interfering RNA (siRNA) molecules, will prove to be powerful antitumor agents.

16 Jan 2007

Nanotechnology continues to advance anticancer gene therapy

Given that cancer is a disease in which genetic errors play a major role, it should come as no surprise that many experts envision a time when gene therapy will play an equally important role in the treatment of cancer.

20 Nov 2006

Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer

Efforts to treat cancer using genes and other oligonucleotides, such as short interfering RNA (siRNA), that turn off the biochemical processes that trigger malignancies have been hindered by difficulties in delivering nucleic acids to tumors.

16 Oct 2006

Promising therapy for Lou Gehrig's disease delivers antisense drug directly to nervous system

Researchers have designed and tested a molecular therapy in animals that they hope will be a major development in the fight to treat amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease.

27 Jul 2006

First complete kit for whole genome amplification and labeling

Kreatech Biotechnology BV has announced the launch of the "Genome-pULSe, arrayCGH Whole Genome Amplification and Labeling Kit" the latest addition to their product portfolio for arrayCGH analysis.

24 Jul 2006

Multiple cancer biomarkers detected simultaneously

Polymerase chain reaction (PCR) technology revolutionized diagnostic medicine and basic research through its ability to amplify and detect minute amounts of specific DNA sequences.

3 Jul 2006

Beams of light used to move, select and trap protein molecules

A paper that outlines a new method to use a beam of light to trap protein molecules and make them dance in space has earned a place in the Proceedings of the National Academy of Sciences Early Edition.

25 Apr 2006

Discovery of new human retrovirus

Howard Hughes Medical Institute researchers and their colleagues have discovered a new retrovirus in humans that is closely related to a cancer-causing virus found in mice. Their findings describe the first documented cases of human infection with a retrovirus that is native to rodents.

10 Apr 2006

Weill Cornell experts publish review of genetic medicine

In an article published in the April issue of Nature Reviews Genetics, two experts at the Weill Medical College of Cornell University sum up the achievements, challenges and promise of a burgeoning field: genetic medicine.

3 Apr 2006

Bioniche granted patent for oligonucleotide technology

Bioniche Life Sciences has announced that it has been granted a European patent - EP1432450 - covering the composition and use of a novel oligonucleotide family for the treatment of cancer entitled: "Therapeutically Useful Triethyleneglycol Cholesteryl Oligonucleotides"

17 Mar 2006

Sirna Therapeutics awarded patent covering large-scale synthesis of RNAi-based therapeutics

Sirna Therapeutics has announced that the United States Patent and Trademark Office (USPTO) has granted Sirna U.S. Patent No. 6,989,442 for the chemical synthesis and manufacturing of ribonucleic acids (RNA).

25 Jan 2006

Edifoligide no better than placebo for clogged veins

A new drug, edifoligide, designed to prevent the clogging of veins used in coronary bypass surgery was no more effective than a placebo, according to the results of a Phase III clinical trial led by researchers at Duke Clinical Research Institute (DCRI).

14 Nov 2005

Nanogen subsidiary, Epoch Biosciences issued new patent

Nanogen announced today its subsidiary, Epoch Biosciences, was issued Patent No. 6,951,930, "Hybridization-Triggered Fluorescent Detection of Nucleic Acids" by the U.S. Patent and Trademark Office.

11 Oct 2005

Human embryonic stem cell lines accumulate changes in their genetic material over time

The findings do not limit the utility of the cells for some types of research or for some future clinical applications, the researchers say, but draw attention to the need to closely monitor stem cell lines for genetic changes and to study how these alterations affect the cells' behavior.

6 Sep 2005

Human embryonic stem cell lines accumulate changes in their genetic material over time

5 Sep 2005

A new method for manipulating macromolecules

The technique uses double-stranded DNA to direct the behavior of other molecules. In previous DNA nanotechnology efforts, duplex DNA has been used as a static lattice to construct geometrical objects in three dimensions.

29 Jun 2005

New clues about the location of genes potentially involved in the most common type of lung cancer

Using technology that makes it possible to zoom in on smaller sections of cell chromosomes than ever before, researchers at Dana-Farber Cancer Institute have identified nearly 100 chromosome regions where genes are either over-copied or missing in non-small cell lung cancer.

27 Jun 2005

Lorus Therapeutics receives patent allowance to protect novel anticancer drug

Lorus Therapeutics today announced that its wholly owned subsidiary, GeneSense Technologies Inc. (GeneSense), has received notice from the European Patent Office of its intention to grant GeneSense's application for a patent of its novel antisense drug, GTI-2501.

9 Jun 2005

Oligonucleotides News and Research

Further Reading

Bristol-Myers Squibb collaborates with Isis Pharmaceuticals

Scientists test technique for identifying newly recognized DNA variations that may influence disease risk

Nanoparticles yield delivery tools for therapeutic nucleic acids

Nanotechnology continues to advance anticancer gene therapy

Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer

Promising therapy for Lou Gehrig's disease delivers antisense drug directly to nervous system

First complete kit for whole genome amplification and labeling

Multiple cancer biomarkers detected simultaneously

Beams of light used to move, select and trap protein molecules

Discovery of new human retrovirus

Weill Cornell experts publish review of genetic medicine

Bioniche granted patent for oligonucleotide technology

Sirna Therapeutics awarded patent covering large-scale synthesis of RNAi-based therapeutics

Edifoligide no better than placebo for clogged veins

Nanogen subsidiary, Epoch Biosciences issued new patent

Human embryonic stem cell lines accumulate changes in their genetic material over time

Human embryonic stem cell lines accumulate changes in their genetic material over time

A new method for manipulating macromolecules

New clues about the location of genes potentially involved in the most common type of lung cancer

Lorus Therapeutics receives patent allowance to protect novel anticancer drug

Biochemistry eBook

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News